Cited 0 times in Scipus Cited Count

Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)

DC Field Value Language
dc.contributor.authorLee, S-
dc.contributor.authorIm, SA-
dc.contributor.authorKim, GM-
dc.contributor.authorJung, KH-
dc.contributor.authorKang, SY-
dc.contributor.authorPark, IH-
dc.contributor.authorKim, JH-
dc.contributor.authorLee, KE-
dc.contributor.authorAhn, HK-
dc.contributor.authorLee, MH-
dc.contributor.authorKim, HJ-
dc.contributor.authorKim, HJ-
dc.contributor.authorLee, JI-
dc.contributor.authorKoh, SJ-
dc.contributor.authorPark, YH-
dc.date.accessioned2022-11-29T01:43:42Z-
dc.date.available2022-11-29T01:43:42Z-
dc.date.issued2020-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/23056-
dc.description.abstractIn the era of CDK4/6 inhibitors in hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, few trials have been specifically studied to compare quality of life between palbociclib plus endocrine therapy (ET) and cytotoxic chemotherapy exclusively in premenopausal women. We aimed to evaluate differences of patient report outcomes (PROs) between palbociclib plus ET and capecitabine. PROs were assessed using EORTC QLQ-C30 at baseline, every 6 weeks, and the end of treatment. All EORTC QLQ-30 scores were maintained from baseline to the end of treatment. Patients treated palbociclib plus ET arm experienced delay in time-to-deterioration of physical functioning (HR = 0.58, 95% CI, 0.36 to 0.84, p = 0.0058), nausea and vomiting (HR = 0.48; 95% CI, 0.32 to 0.73, p = 0.0005), and diarrhea (HR = 0.42; 95% CI, 0.27 to 0.65, p = 0.001). There was a numeric trend for worsening of insomnia (HR = 1.43; 95% CI, 0.96 to 2.16, p = 0.079) and favoring of appetite loss (HR = 0.69, 95% CI, 0.44 to 1.07, p = 0.09) in the palbociclib plus ET arm. Premenopausal patients with palbociclib plus ET maintained QoL without compromising treatment efficacy.-
dc.language.isoen-
dc.titlePatient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)-
dc.typeArticle-
dc.identifier.pmid33167305-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694364-
dc.subject.keywordpalbociclib-
dc.subject.keywordcapecitabine-
dc.subject.keywordbreast neoplasm-
dc.subject.keywordpremenopause-
dc.subject.keywordpatient-reported outcome measures-
dc.contributor.affiliatedAuthorKang, SY-
dc.type.localJournal Papers-
dc.identifier.doi10.3390/cancers12113265-
dc.citation.titleCancers-
dc.citation.volume12-
dc.citation.number11-
dc.citation.date2020-
dc.citation.startPage3265-
dc.citation.endPage3265-
dc.identifier.bibliographicCitationCancers, 12(11). : 3265-3265, 2020-
dc.identifier.eissn2072-6694-
dc.relation.journalidJ020726694-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
33167305.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse